Key clinical point: Low-dose azithromycin prophylaxis reduces exacerbations and other respiratory events in primary airway deficiency.
Major finding: Relative to placebo over 2 years, low-dose azithromycin significantly reduced the annual rate of exacerbations by 1.6 episodes per patient.
Data Source: Phase 2 multicenter, placebo-controlled trial.
Disclosures: Dr. Milito reported no potential conflicts of interest.
ERS 2019; Milito C et al. J Allergy Clin Immunol 2019;144: 584-593